Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB), Insmed (INSM) and Tenet Healthcare (THC)
Robust Pipeline and Financial Stability Underpin Buy Rating for Inmune Bio
Inmune Bio's Promising INKmune Therapy and Strong Financials Merit a Buy Rating
Inmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financials
Inmune Bio's INB03 Shows Promise as Pan-Immune Checkpoint Inhibitor: A Buy Rating From Analyst Joel Beatty
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer's Treatment Developments
BTIG Remains a Buy on Inmune Bio (INMB)
Buy Rating Affirmed: Inmune Bio's XPro Progresses With FDA's Green Light and Unique Therapeutic Approach
Inmune Bio's Buy Rating Affirmed Amid Positive Alzheimer's Program Developments
Buy Rating Affirmed for INmune Bio Amid Progress in Cancer Therapy Trials and Financial Stability
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Idexx Laboratories (IDXX)
Buy Rating for Inmune Bio Backed by Promising Therapeutic Developments and Regulatory Progress
Buy Rating on Inmune Bio: Expansion and Promising Developments in Alzheimer's Treatment Trials
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Inmune Bio (INMB) and Guardant Health (GH)
Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Universal Health (UHS) and Inmune Bio (INMB)
Inmune Bio (INMB) Receives a Buy From BTIG
Inmune Bio (INMB) Receives a Buy From Robert W. Baird
Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Inmune Bio (INMB)
Maxim Group Sticks to Its Buy Rating for Inmune Bio (INMB)